Section 14(a) of the Securities Exchange Act and Delaware fiduciary law require that shareholders receive complete and accurate disclosures before voting on a merger. When the proxy statement omits or misstates material information, shareholders have a remedy.
Attorney Advertising. Prior results do not guarantee a similar outcome.
When a public company announces a merger or acquisition, federal and state law require the company to provide shareholders with the information they need to make an informed decision about how to vote. The principal disclosure document is the proxy statement (typically a Schedule 14A) or, in cash-out mergers, a tender offer statement (Schedule TO).
Section 14(a) of the Securities Exchange Act of 1934 and SEC Rule 14a-9 prohibit false or misleading statements in proxy solicitations. Section 13(e) and Rule 13e-3 apply to going-private transactions. Delaware fiduciary law imposes parallel obligations on directors to disclose all material information when seeking shareholder action.
When a proxy statement omits or misstates information material to a reasonable investor’s vote, shareholders harmed by the omission have the right to seek remedies — typically through litigation that produces supplemental disclosures before the vote.
The following are recurring categories of disclosure failures we evaluate in proxy filings:
The board's financial projections — used by the financial advisor in its fairness opinion — are often presented selectively. Unlevered free cash flow, EBITDA projections, terminal multiples, and DCF inputs must be disclosed in enough detail for shareholders to evaluate whether the deal price reflects fair value.
The proxy must disclose the comparable-company, comparable-transaction, premiums-paid, and sensitivity analyses that informed the fairness opinion. Selective summary or omission of unfavorable data points is a recurring disclosure issue.
Conflicts at the financial advisor (prior fees, ongoing relationship), the directors (continuing roles, personal benefits), or management (retention agreements, change-in-control payments, post-transaction employment) must be disclosed in detail.
The proxy must describe the sale-process timeline, the alternatives the board considered, the topping-bid analysis, and the deal-protection provisions (no-shop covenants, matching rights, termination fees) that shaped the bidding dynamics.
Where the company's internal forecasts differed materially from public guidance — and the merger price reflects the higher private forecast or the lower public guidance — the differential is itself material to the vote.
Live page renders an empty section divider here (a stray heading-less band). Omit any empty Elementor section between blocks; do not output a heading or rule with no content beneath it.
In addition to §14(a), shareholders have parallel claims under Delaware fiduciary law. Directors approving a merger have duties to maximize shareholder value (in arms-length cash deals, the Revlon duty) and to disclose all material information when seeking shareholder action (the Stroud v. Grace / Loudon v. Archer-Daniels-Midland duty of disclosure).
Delaware fiduciary claims sit in the Delaware Court of Chancery (or other state-of-incorporation courts) and operate on a different procedural track from federal §14(a) claims. We work with experienced Delaware co-counsel on Chancery filings.
Merger objection cases move on a tight schedule because they are tied to the shareholder vote, which is typically set 30–60 days after the proxy mailing.
Company files preliminary or definitive proxy with the SEC.
We review the proxy, financial-advisor presentations, and sale-process timeline.
Issue a §14(a) complaint and/or shareholder demand letter.
Company files supplemental disclosures correcting omissions.
Case resolves via supplemental disclosures, financial settlement (where Delaware fiduciary claims support it), or appropriate remedy.
Where supplemental disclosures do not adequately address material omissions, the litigation can extend past the vote into appraisal, fiduciary, or post-closing damages proceedings.
Issues a Chancery or federal judge would describe as plainly material — financial projection differentials, conflict disclosures, banker fee structures, sale-process irregularities — not boilerplate disclosure objections.
The 30–60 day window between proxy issuance and the shareholder vote is the operational tempo of this practice. Our investigations are designed to move at that speed.
Federal Rule 11 and Delaware Chancery Rule 11 requirements are real. So is the reputational cost of filing weak cases. We don't file for lead position alone. We file because the facts support a §14(a) or fiduciary claim.
No out-of-pocket cost to the shareholder. Fees are paid only out of any recovery, subject to court approval. Fee terms are disclosed in the written retainer agreement.
Outcomes vary. Section 14(a) disclosure cases typically resolve via supplemental proxy disclosures filed before the vote — additional projection detail, conflicts disclosures, sale-process detail — giving shareholders better information. Delaware fiduciary claims (under Revlon, QVC, and post-Corwin doctrines) can resolve in financial settlements for the class: corrections to the deal price, cash compensation, post-closing damages, or recoveries tied to statutory appraisal rights under DGCL §262. Some matters resolve in a combination of both.
They generally do not. The remedy in disclosure cases is supplemental disclosure — not deal blockage. Cases that seek to block deals (typically Delaware fiduciary claims under Revlon) are a different category.
That is your decision. Selling typically forfeits any right to participate as a class member in the matter. Many merger objection cases conclude with the merger closing on schedule. Speak with your tax and financial advisors before deciding.
For §14(a) federal claims, you generally need to have held shares as of the record date set by the company for the vote. For Delaware fiduciary claims, contemporaneous ownership rules apply (you must own shares at the time of the alleged misconduct and continuously through the suit).
Yes. Institutional investors often have the largest holdings and are well-positioned to lead these cases — particularly where appraisal rights or post-closing damages are in play.
Free case evaluation. Contingency basis — no out-of-pocket cost.
Bind this rail to the Investigation CPT filtered to investigation_type = derivative, capped at 2–3. If the loop returns zero, hide this block via Elementor display condition rather than show a heading over an empty rail.
Tell us your holdings; we flag you when an investigation matches a class period. Free. No obligation.
Free, confidential consultation. We move on the proxy timeline.